SG Americas Securities LLC Sells 29,030 Shares of MiMedx Group, Inc (NASDAQ:MDXG)

SG Americas Securities LLC reduced its position in MiMedx Group, Inc (NASDAQ:MDXG) by 34.8% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 54,355 shares of the company’s stock after selling 29,030 shares during the quarter. SG Americas Securities LLC’s holdings in MiMedx Group were worth $413,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of MDXG. First Light Asset Management LLC bought a new position in MiMedx Group in the fourth quarter worth $32,168,000. Norges Bank bought a new position in MiMedx Group in the fourth quarter worth $4,020,000. JPMorgan Chase & Co. lifted its position in MiMedx Group by 133.1% in the fourth quarter. JPMorgan Chase & Co. now owns 693,106 shares of the company’s stock worth $6,668,000 after purchasing an additional 395,739 shares during the period. Meros Investment Management LP bought a new position in MiMedx Group in the fourth quarter worth $3,801,000. Finally, Arrowstreet Capital Limited Partnership lifted its position in MiMedx Group by 484.2% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 362,481 shares of the company’s stock worth $3,487,000 after purchasing an additional 300,433 shares during the period. 79.15% of the stock is owned by institutional investors.

MiMedx Group Stock Performance

MiMedx Group stock opened at $5.96 on Wednesday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.70 and a quick ratio of 4.13. The stock has a fifty day moving average price of $6.60 and a two-hundred day moving average price of $7.77. MiMedx Group, Inc has a 52-week low of $5.47 and a 52-week high of $10.14. The firm has a market capitalization of $880.29 million, a P/E ratio of 22.07 and a beta of 1.82.

MiMedx Group (NASDAQ:MDXG) last announced its earnings results on Wednesday, April 30th. The company reported $0.06 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.06. MiMedx Group had a return on equity of 22.70% and a net margin of 11.40%. The company had revenue of $88.21 million during the quarter, compared to analyst estimates of $86.32 million. As a group, analysts anticipate that MiMedx Group, Inc will post 0.3 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have issued reports on MDXG shares. Wall Street Zen upgraded MiMedx Group from a “hold” rating to a “buy” rating in a research note on Friday, June 6th. Cantor Fitzgerald reiterated an “overweight” rating and set a $13.00 price objective on shares of MiMedx Group in a research note on Thursday, February 27th.

Insider Activity

In other news, CEO Joseph H. Capper acquired 200,000 shares of the stock in a transaction that occurred on Friday, May 2nd. The stock was purchased at an average cost of $6.34 per share, for a total transaction of $1,268,000.00. Following the completion of the transaction, the chief executive officer now directly owns 529,530 shares in the company, valued at $3,357,220.20. This trade represents a 60.69% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.70% of the stock is currently owned by corporate insiders.

MiMedx Group Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.